中晚期卵巢上皮性癌新辅助化疗与耐药的研究进展

Research Progress on Neoadjuvant Chemotherapy and Drug Resistance for Advanced Ovarian Epithelial Carcinoma

卵巢癌是女性生殖系统常见的恶性肿瘤之一,在所有妇科恶性肿瘤中发病率位居第三,病死率更是居于首位,其中以上皮性卵巢癌最为常见。据统计,晚期卵巢上皮性癌五年的生存率仅为30%~40%。新辅助化疗是指在术前给予全身化疗,使肿瘤缩小或消失后再进行手术治疗的一种治疗手段。该治疗手段在结直肠癌、肺癌、乳腺癌等治疗中广泛应用。然而,目前,新辅助化疗对中晚期卵巢癌的治疗效果仍存在争议性。在新辅助化疗过程中患者可能会发生耐药,导致病灶进一步增大或扩散,从而失去手术机会。因此,本文就中晚期卵巢上皮性癌新辅助化疗与耐药的相关研究进展作一综述。

Ovarian cancer is one of the most common malignant tumors in female reproductive system,with the third incidence rate among gynecological malignant tumors,and the first mortality rate,and epidermal ovarian cancer was the most common.According to statistics,five-year survival rate of advanced ovarian epithelial cancer was only 30%to 40%.Neoadjuvant chemotherapy refers to surgical treatment after systemic chemotherapy before surgery to shrink or disappear the tumor,which is widely used in colorectal cancer,lung cancer,breast cancer and other tumors.However,its benefits in advanced ovarian cancer are still controversial.During process of neoadjuvant chemotherapy,patients may develop drug resistance,which may cause further enlargement or spread of the lesion,and lose opportunity for surgery.Therefore,the article reviews research progress on neoadjuvant chemotherapy and drug resistance of advanced ovarian epithelial cancer.